BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36749556)

  • 21. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.
    Hester C; Nassour I; Adams-Huet B; Augustine M; Choti MA; Minter RM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Yopp AC
    J Gastrointest Surg; 2018 Dec; 22(12):2080-2087. PubMed ID: 30030718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
    Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
    Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?
    Ayabe RI; Paez-Arango N; Estrella JS; Newhook TE; Tzeng CD; Chun YS; Lee S; Javle M; Vauthey JN; Tran Cao HS
    HPB (Oxford); 2023 Apr; 25(4):472-480. PubMed ID: 36781357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it safe to administer neoadjuvant chemotherapy to patients undergoing hepatectomy for intrahepatic cholangiocarcinoma? ACS-NSQIP propensity-matched analysis.
    Choi WJ; Ivanics T; Claasen MPAW; Gallinger S; Hansen B; Sapisochin G
    HPB (Oxford); 2022 Sep; 24(9):1535-1542. PubMed ID: 35474005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
    Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
    Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma.
    Rana A; Hong JC
    Curr Opin Gastroenterol; 2012 May; 28(3):258-65. PubMed ID: 22333563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
    Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
    Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease.
    Utuama O; Permuth JB; Dagne G; Sanchez-Anguiano A; Alman A; Kumar A; Denbo J; Kim R; Fleming JB; Anaya DA
    Ann Surg Oncol; 2021 Apr; 28(4):1939-1949. PubMed ID: 33415559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
    Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
    Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of neoadjuvant chemotherapy based on our resectability criteria for locally advanced perihilar cholangiocarcinoma.
    Gyoten K; Kuriyama N; Maeda K; Ito T; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Mizuno S
    Langenbecks Arch Surg; 2023 Jul; 408(1):261. PubMed ID: 37392289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma.
    Macfie R; Berger Y; Liu H; Li T; Imtiaz S; Ang C; Sarpel U; Hiotis S; Labow D; Golas B; Cohen NA
    Ann Surg Oncol; 2023 Aug; 30(8):5027-5034. PubMed ID: 37210446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
    Rizzo A; Brandi G
    Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does Adjuvant Therapy Benefit Low-Risk Resectable Cholangiocarcinoma? An Evaluation of the NCCN Guidelines.
    Munir MM; Ruff SM; Endo Y; Lima HA; Alaimo L; Moazzam Z; Shaikh C; Pawlik TM
    J Gastrointest Surg; 2023 Mar; 27(3):511-520. PubMed ID: 36538255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
    Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
    Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    Mazzaferro V; Gorgen A; Roayaie S; Droz Dit Busset M; Sapisochin G
    J Hepatol; 2020 Feb; 72(2):364-377. PubMed ID: 31954498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.
    Rhodin KE; Liu A; Bartholomew A; Kramer R; Parameswaran A; Uronis H; Strickler J; Hsu D; Morse MA; Shah KN; Herbert G; Zani S; Nussbaum DP; Allen PJ; Lidsky ME
    Ann Surg Oncol; 2023 Aug; 30(8):4813-4821. PubMed ID: 37188803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.